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Faced by an explosion in available evidence for 
multiple new treatments, busy clinicians value 
guidelines that are clear, reliable, unbiased and locally 
applicable. Finding them can be difficult, however. 
The science of guideline development has moved 
rapidly in the past decade, resulting in a more robust and systematic 
process. However, just as the language of evidence-based medicine 
can be subverted to sound convincing while hiding errors and biases, 
so too guidelines may look convincing but lack many of the elements 
needed to ensure quality of care. In particular, the pharmaceutical 
and health technology industries are intensely aware of the marketing 
potential offered by widely disseminated and ostensibly neutral 
documents that ultimately influence medical practice.
A few examples illustrate the potential challenges. The recently 
published JNC8 guidelines on hypertension management[1] followed 
a very robust process,[2] and yet ended with some of the authors 
taking a dissenting view,[3] which at the least raised concerns about 
the credibility of the guideline. The European Society of Cardiology 
guideline on perioperative beta-blockade was the subject of potential 
conflict of interest concerns when the guideline chairperson was 
investigated for scientific misconduct related to the DECREASE family 
of trials.[4] At the time it was estimated that 10 000 iatrogenic deaths 
could have been prevented annually by refraining from following 
this guideline.[5] A 2009 review of cardiology guidelines[6] found that 
of 7 000 recommendations only 11% were based on randomised 
controlled trial (RCT) evidence, and a 2011 study of infectious 
disease guidelines[7] reported a similar finding, with only 14% of 
4 000 recommendations having RCT backing. These observations 
were further corroborated in a recent systematic analysis in which the 
validity of guidelines published by interventional medical societies was 
investigated. It was established that most associated guidelines failed to 
grade the evidence, and when graded, lower-quality evidence was used. 
Furthermore, most guidelines failed to disclose conflicts of interests.[8]
The US Institute of Medicine has defined clinical practice 
guidelines as ‘statements that include recommendations intended 
to optimise patient care that are informed by a systematic review of 
evidence and an assessment of the benefits and harms of alternative 
care options’.[9] They are important in influencing public health policy, 
promoting distributive justice and advocating better healthcare 
delivery for those in need.[10,11] The increased frequency with which 
clinical treatment guidelines/recommendations are being published 
in South Africa (SA) is of great significance in a resource-poor 
country, accentuating the need to ensure their validity. Consequently, 
heightened responsibility is called for in terms of applying due process 
throughout the development and publication of all guidelines.
Evidence collection and synthesis
The application of the evidence-based medicine philosophy, while 
not infallible, is central to the promotion of a fair and equitable 
distribution of resources. Sackett et al.[12] define evidence-based 
medicine as ‘the conscientious, explicit, and judicious use of current 
best evidence in making decisions about the care of individual 
patients. The practice of evidence based medicine means integrating 
individual clinical expertise with the best available external clinical 
evidence from systematic research.’ By individual clinical expertise, 
they refer to the proficiency and judgement that individual clinicians 
acquire through clinical experience and clinical practice.[12] While it 
is accepted that ‘expert opinion’ falls low down on the hierarchy of 
sources of clinical evidence, if principles of evidence-based medicine 
are to be applied in the true spirit of their intention, then the need for 
consensus opinion is fundamental.[13] It is in this context that clinical 
guidelines and recommendations contribute profoundly towards the 
process of decision making and resource allocation.
Making recommendations
Priority setting is challenging in any health system. Irrespective of 
our sector of practice, financial resources are finite and there are 
competing interests in terms of resource allocation. The demand 
for health services exceeds available resources, and in order to meet 
the health needs of a community, allocation of health services and 
associated financial resources must be prioritised.[14] As Chinnock et al. 
state,[15] wherever healthcare is provided, it is essential to know which 
interventions work, which do not, and which are likely to be harmful. 
This is especially important in situations where health problems are 
severe and scarcity of resources makes it vital that they are not wasted.
In a 2011 position paper regarding the effective and efficient 
conservation and distribution of healthcare resources, the American 
College of Physicians[16] noted the requirement for a transparent and 
publically acceptable process for making resource allocation decisions 
with a focus on medical efficacy, clinical effectiveness and need, with 
consideration for cost, based on the best available medical evidence. 
It is important to emphasise that rationing in this context is not 
about the denial of care, but rather about choosing clinically effective 
alternatives based on peer-reviewed medical evidence to provide 
clinically appropriate and cost-effective care that maximises value.[16]
Recommendations therefore need to integrate evidence, concepts of 
best practice and resource constraints in order to set practice directions 
and provide tools to audit the care delivered. This process is seldom 
easy, and it is useful for practitioners to understand the strength of the 
recommendation in order to decide how best to apply it in their practice.
Clinical guidelines and the SAMJ
The SAMJ (and its HMPG ‘siblings’) has recognised the important 
role that guidelines play in setting standards of clinical practice as 
well as the imperative of following transparent due process in their 
development and publication. To this end, it has sought to establish a 
formalised peer-review process.
In fulfilling this obligation, we introduce the readership to the 
AGREE II instrument as an objective appraisal mechanism against 
which prospective clinical guidelines will be assessed before their 
publication. This internationally developed and validated quality 
assessment tool is available in the public domain (at www.agreetrust.
org) and can be applied generically to assess the quality of guidelines 
across all disease areas and at any stage of the healthcare continuum, 
whether it be screening, diagnosis or treatment.[17] It can also be used 
to inform guideline development processes and provides guidance on 
the type of information that should be reported in a guideline.
The purpose of the AGREE II tool is to provide a framework (from 
Brouwers et al.[17]) to: (i) assess the quality of guidelines; (ii) provide 
a methodological strategy for the development of guidelines; and (iii) 
inform what information ought to be reported in guidelines, and how 
it should be reported.
AGREE II outlines six unique domains of guideline quality:[17]
Domain 1. Scope and purpose ‘is concerned with the overall aim 
of the guideline, the specific health questions, and the target patient 
population’.
AGREE to disagree: Critical appraisal and the publication of 
practice guidelines
EDITORIAL
346       May 2014, Vol. 104, No. 5
Domain 2. Stakeholder involvement ‘focuses on the extent to which 
the guideline was developed by the appropriate stakeholders and 
represents the views of its intended users’.
Domain 3. Rigour of development ‘relates to the process used 
to gather and synthesise the evidence, the methods to formulate 
the recommendations, and to update them’. It ensures an explicit 
link between the recommendation and the supporting evidence and 
facilitates an assessment of whether health benefits, adverse effects 
and risks were considered in formulating the recommendations.
Domain 4. Clarity of presentation ‘deals with the language, 
structure, and format of the guideline’.
Domain 5. Applicability ‘pertains to the likely barriers and 
facilitators to implementation, strategies to improve uptake, and 
resource implications of applying the guideline’.
Domain 6. Editorial independence ‘is concerned with the 
formulation of recommendations not being unduly biased by 
competing interests’. Any potential conflict of interest must be 
reported and appropriately managed.
An editorial sub-committee under the leadership of Prof. Marc 
Blockman has been appointed by the SAMJ to undertake this 
responsibility. This represents an important step in ensuring the 
rigour and validity of future guidelines available in SA.
Conclusion
A quality guideline is one in which there is confidence that the 
potential biases of guideline development have been addressed 
adequately, one which is deemed to be externally valid via a peer-
review process, and one which is locally applicable and feasible. [18] 
The introduction of this tool, as a critical appraisal mechanism, 
is an important advance in the use of evidence-based medicine 
principles (in its true sense) in the development and publication 
of practice guidelines in SA. Through ensuring the application of 
sufficient rigour in the development process, there is a firm belief 
that a clinician’s ability to make informed clinical decisions will 
be enhanced, ultimately leading to improved patient care through 
discouraging the use of ineffective and wasteful interventions. This, 
in turn, will result in more efficient resource utilisation, will elevate 
the level of trust in the guideline itself, and is likely to impact on the 
ability and willingness to implement such a guideline in practice.
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